These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1105868)

  • 1. [Treatment of Parkinson disease with Bromocriptine (CB 154 Sandoz) (author's transl)].
    Jacobides GB; Audibert A
    Ther Umsch; 1975 Jul; 32(7):469-71. PubMed ID: 1105868
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of parkinsonian syndromes by bromocriptin].
    Gautier JC; Durand JP
    Nouv Presse Med; 1977 Jan; 6(3):171-4. PubMed ID: 319421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic usefulness of bromoergocriptine (CB-154 Sandoz) in patients with galactorrhea (author's transl)].
    González Colindres JA; Canales ES; Levinson G; Zárate A; Sorta J
    Rev Invest Clin; 1975; 27(2):135-8. PubMed ID: 1237173
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of lergotrile on schizophrenia & drug induced parkinsonism.
    Small JG; Kellams JJ; Milstein V; Klapper M; Lemberger L
    Commun Psychopharmacol; 1977; 1(5):461-7. PubMed ID: 23919
    [No Abstract]   [Full Text] [Related]  

  • 5. [Endocrine effects of bromocryptin in patients with Parkinsonism].
    Barreca T; Gianrossi R; Gallamini A; Nizzo MC; Queirolo A
    Boll Soc Ital Biol Sper; 1976 Oct; 52(19):1564-7. PubMed ID: 1037379
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of acromegaly with bromocriptine (CB 154)].
    Schwinn G; Dirks H; Köbberling J
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1896-9. PubMed ID: 801095
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of Parkinsonian syndrome using amantadine hydrochloride].
    Schubert U; Fischer GJ; Glass J
    Z Arztl Fortbild (Jena); 1975 May; 69(9):469-76. PubMed ID: 1106004
    [No Abstract]   [Full Text] [Related]  

  • 8. ["Use of bromocriptin (CB 154) in the treatment of puerperal and pathological lactation" (author's transl)].
    del Pozo E
    Schweiz Rundsch Med Prax; 1976 Feb; 65(7):181-5. PubMed ID: 1250831
    [No Abstract]   [Full Text] [Related]  

  • 9. Pergolide in late-stage Parkinson disease.
    Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD
    Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic effects of cyticholine (cytidine-diphospho-choline) in Parkinsonian syndrome].
    Ruggieri S; Zamponi A; Casacchia M; Agnoli A
    Clin Ter; 1976 Sep; 78(6):515-25. PubMed ID: 797506
    [No Abstract]   [Full Text] [Related]  

  • 11. [Letter: Efficacy of bromocriptine in 2 cases of levodopa-resistant parkinsonism].
    Kissel P; Andre JM; Jacquier A
    Nouv Presse Med; 1976 Jan; 5(4):210. PubMed ID: 1264671
    [No Abstract]   [Full Text] [Related]  

  • 12. [The "problem" of stopping loctation prevention and suppression with CB 154 (author's transl)].
    Schneider D
    Schweiz Rundsch Med Prax; 1976 Jan; 65(2):54-6. PubMed ID: 1257199
    [No Abstract]   [Full Text] [Related]  

  • 13. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations.
    Stibe C; Lees A; Stern G
    Lancet; 1987 Apr; 1(8537):871. PubMed ID: 2882282
    [No Abstract]   [Full Text] [Related]  

  • 14. [Oral lisuride in Parkinson's disease].
    Obeso JA; Luquin MR; Martínez Lage JM
    Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
    [No Abstract]   [Full Text] [Related]  

  • 15. Stabilographic evaluation of dopaminergic and anticholinergic treatment of parkinsonism.
    Cernacek J; Brezny I; Jagr J
    Agressologie; 1973; 14(Spec No D):83-7. PubMed ID: 4608340
    [No Abstract]   [Full Text] [Related]  

  • 16. [The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
    Sommer H; Fischer GJ; Quandt J
    Folia Clin Int (Barc); 1974 Oct; 24(10):681-95. PubMed ID: 4279185
    [No Abstract]   [Full Text] [Related]  

  • 17. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA; Burns RS; Calne DB
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical efficacy of nicergoline in cerebrovascular diseases. Statistical study].
    Guardamagna C; Negri S
    Minerva Cardioangiol; 1972 Nov; 20(11):636-41. PubMed ID: 4566130
    [No Abstract]   [Full Text] [Related]  

  • 19. A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease.
    Klawans HL; Tanner CM; Glatt S; Goetz CG
    Adv Neurol; 1983; 37():75-83. PubMed ID: 6344592
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
    Schneider E; Hubener K; Fischer PA
    Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.